A carregar...
Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study
Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are antihyperglycaemic agents with weight‐lowering effects. The efficacy and safety of the SGLT2 inhibitor canagliflozin as add‐on therapy in Japanese patients with type 2 diabetes mellitus (T...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6033027/ https://ncbi.nlm.nih.gov/pubmed/29473709 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13267 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|